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Oral Presentations S163\1% in mice given HSC), accompanied by a substantial increase of
host NK cells (median 14% vs\1%; 6.3 vs\0.4 x10^5 cells). Donor
CD4 TC in the BM expressed high levels of IFNg (30-50%), which
exceeded IFNg secretion in control groups (3-15%). Similar find-
ings of engraftment failure due to donor CD4 TC were noted
when mice were conditioned with total lymphoid irradiation (TLI:
17240 cGy): while recipients of HSC alone were mixed chimeras
in all lineages, those given HSC +TC failed to engraft with T and
B cells, had only marginal myeloid engraftment, but increased pro-
portions of host NK cells in the PB. We conclude that after non-
myeloablative conditioning transplantation of pure HSC can result
in superior immune reconstitution and donor chimerism as com-
pared to grafts supplemented with CD4 TC. These results are of
broad significance, as it is generally believed that TC augment donor
HSC engraftment. The way in which CD4 TC retard engraftment
appears to be by induction of inflammation within the BMmicroen-
vironment and activation of host lymphoid populations that mediate
resistance. IFNg, which is a known regulator of innate and acquired
immune responses, may be central in activating host CD4 TC,
enhancing NK cell mediated rejection of the graft and/or suppres-
sion of donor hematopoiesis.23
CCR5 EXPRESSION ON CIRCULATING BLOOD DC POST-ALLOGENEIC HE-
MOPOIETIC CELL TRANSPLANT IS HIGHLY PREDICTIVE FOR THE DEVEL-
OPMENT OF CLINICALLY SIGNIFICANT ACUTE GRAFT VERSUS HOST
DISEASE
Sartor, M.M.1, Lau, J.1, Gottlieb, D.J.2, Bradstock, K.F.2 1Westmead
Millenium Institute, Sydney, NSW, Australia; 2Westmead Hospital,
Sydney, NSW, Australia
Introduction:Dendritic cells (DC) are central to the development
of acute graft-versus-host disease (GvHD) following allogeneic he-
matopoietic cell transplantation (alloHCT). Because DC migration
is tightly regulated by the interaction between chemokine receptors
on DC and their ligands, we investigated the relationship between
the severity of acute GvHD and the expression of the chemokine
receptors CCR5 and CCR7 on CD11c+ myeloid and CD11c- plas-
macytoid DC from the peripheral blood of 32 patients post al-
loHCT.
Methods: Peripheral blood was collected twice weekly up to day 100
post transplant. The expression of each chemokine receptor on
CD11c+ and CD11c- DC was calculated using multiparameter
flow cytometry. The percentage of CD11c+ DC expressing a given
receptor was added to the percentage of CD11c- DC expressing
the same receptor to give a maximum score that could vary from
0 to 200%.
Results: Eleven of 32 patients developed moderate to severe acute
GvHD (grade II-IV), the remaining 21 patients developed either
no GvHD or only grade I GvHD. The percentage of DC express-
ing either CCR5 or CCR7 was correlated with the development of
acute GvHD. CCR7 expression was detected in 13 of 32 patients
post-HCT with a median of 2.3% of DC positive (range 0 to
39%). CCR7 expression on DC showed no association with the se-
verity of acute GvHD (p5 1.0). In contrast, higher CCR5 expres-
sion was detected on DC in patients developing grade II-IV
GvHD (median 98.0%, SEM 9.1%) than in those with grade 0-I
GvHD (median 5.2%, SEM 5.1%) p\0.0001. All eleven patients
with grade II-IV GvHD expressed CCR5 at a level of .35% of
myeloid and plasmacytoid DC. Only two of 21 patients with grade
1 GvHD expressed CCR5 at the same level (66% and 94%). Most
importantly, the expression of CCR5 preceded the development of
moderate to severe GvHD in all patients by a median of 19 days
(range 2 to 47 days, SEM 4.3 days). Using a receiver operator
curve analysis, CCR5 expression above 35% demonstrated a sensi-
tivity of 100% and a specificity of 90.5% for predicting grade II-IV
GvHD.
Conclusion:Expression of CCR5 on circulatingDCpost allo-HCT
predicts for the development of moderate to severe GvHD, and de-
tection could allow earlier therapeutic intervention prior to the de-
velopment of clinical GVHD.24
EX-VIVO EXPANDED AND FRESHLY ISOLATED CD4+CD25+FOXP3+ REG-
ULATORY T CELLS SUPPRESS MURINE ACUTE GVHD WITH DIFFERENT
POTENCY
Sega, E.I.1, Leveson-Gower, D.1, Nguyen, V.H.2, Negrin, R.S.1 1Stan-
ford University, Stanford, CA; 2University of Chicago, IL
Using murine models of acute GVHD in which allogeneic bone
marrow cells are transplanted into lethally irradiated hosts, we and
others have shown that donorCD4+CD25+Foxp3+ regulatoryT cells
(Treg) are able to suppress GVHD induced by donor allogeneic con-
ventional T cells (Tcon). The potential clinical use of Treg is limited
by their low number. To overcome this problem, expansion of Treg
has been performed, however, there has not been a head-to-head
comparison of the function of expanded vs. fresh Treg. Highly puri-
fied CD4+CD25+Foxp3+ T cells (.98% purity) were expanded
using anti-CD3/CD28 dynabeads and 1000 U/ml IL-2. Treg cul-
tured for five days expanded up to 13 fold while maintaining high
Foxp3 expression levels (85-90%). The expanded Treg (eTreg)
were evaluated in an in vivo acute GVHD mouse model in direct
comparison with freshly isolatedTreg (fTreg) using a novel biolumi-
nescent imaging assay (BLI) that allowed for quantitative assessment
of Tcon proliferation in addition to traditional metrics of GVHD se-
verity. Expanded Treg were significantly more effective at suppress-
ing the early proliferation of Tcon than an equal number of fTreg
(P\0.0001). On day 6, mice that received Tcon and eTreg had
a mean BLI signal of 1.5106 photons/sec/mouse, four times lower
than the signal of mice receiving Tcon and fTreg (5.8106 photons/
sec/mouse). The difference in potency may be explained by the in-
creased number of eTreg compared to fTreg that were re-isolated
from peripheral lymph nodes (PLN) (40,600 total eTreg/PLN/
mouse vs. 5,200 total fTreg/PLN/mouse) at day 5, suggesting that
expanded Treg arrived and proliferated in PLN faster than the fresh
Treg. However, over time, the eTreg lose their protective capabil-
ities and, in order to suppress GVHD symptoms and improve sur-
vival, a greater number of eTreg were required compared to
fTreg. On day 37, the mean GVHD score for the Tcon alone group
was 8.66 0.74. Fresh Treg added at 1:1 ratio with Tcon decreased
GVHD score to 1.46 0.25 (p\ 0.0001). Ex-vivo expanded Treg
demonstrated a dose-dependent decrease in GVHD score, although
four times more eTreg were needed to obtain a similar reduction in
GVHD score (0.336 0.3, p5 0.0002). Although eTreg are less
potent at suppressing GVHD than fTreg, the greater numbers
achievable by short-term culture makes them viable option for treat-
ment ofGVHD, however, increased ratios of Treg:Tcon are likely to
be required.25
ANALYSIS OF GRAFT FAILURE IN 168 PATIENTS WITH FANCONI ANEMIA
SUBMITTED TO STEM CELL TRANSPLANTATION IN A SINGLE BRAZILIAN
INSTITUTION
Sola, C.B.S., Nabhan, S.K., Bitencourt, M.A., Ribeiro, L., Morando, J.,
Pasquini, R., Zanis Neto, J., Bonfim, C.M.S. Hospital de Clinicas
UFPR, Curitiba, Parana, Brazil
Background:Graft failure (GF) is a serious and fatal complication
that can occur in up to 30% of Fanconi anemia (FA) patients sub-
mitted to hemaopoietic stem cell transplantation. (HSCT). The
goal of this study was the analysis of risks factors for GF in patients
with FA.
Patient andMethods Between January 1985 and July 2008, 203 pts
with FA were submitted to an HSCT and 168 were evaluable for en-
graftment .Thirty-one had graft failure (group A), while 140pts had
an adequate engraftment (group B). Pts in group A had a longer du-
ration of the disease when compared to pts in group B (40 versus 19
months – p5 0,004) and they were also more transfused (43 versus 8
– p\0,001). Stem cell source: Group A: Bone marrow (BM) 65%
and umbilical cord blood (UCB) 35%. Group B: 85% BM and
15%UCB.Unrelated donors (UD) were used in 68%of pts in group
A and 28% in group B (p\0,001); there were also less compatible
transplant in group A (57 versus 79%- p5 0,01). A de-escalation
dose of cyclophosphamide was used for the majority of pts receiving
a related HSCT while a fludarabine based regimen was used in pts
with UD. GVHD prophylaxis consisted of cyclosporine and metho-
trexate in the majority of pts.
S164 Oral PresentationsResults: In the related group we observed 8 graft failures (GF): 5
pts had an HLA identical sibling (HLA id sib) donor and 3 had
other related (OR) donors. In this group, 3 pts had primary GF
and received a 2nd HSCT, but just one is alive. Five pts had second-
ary GF, in a median of 149 days (156-365) after the first transplant.
Three had HLA id sib and two OR donors. Four pts received a 2nd
HSCT using the same donor and 2 are alive. In the unrelated
group we had 11 BM transplants (10pts had primary GF and one
had a secondary GF) and 12 UCB transplants (all pts had primary
GF). Only one pt in this group is alive after 2nd transplant (BM). In
univariate analysis, the variables that influenced the cumulative in-
cidence (CI) of GF were the use of unrelated versus related donor
(30  10%) and transfusions (. 25 units) 30% x 6% The use of
fludarabine was associated with lower CI of GF in the unrelated
group.
Conclusions: Graft failure is a very serious complication after
HSCT and in this study, it was more frequently associated with
the use of unrelated mismatched donors, more transfunded pts and
without fludarabine in the conditioning in the group of UD.New
conditionings and reduction in time to find an unrelated donor
may be alternatives to reduce GF in FA patients.26
SAFETY AND CLINICAL EFFICACY OF EARLY VACCINATION AFTER NON-
MYELOABLATIVE TRANSPLANT FOR ADVANCED CHRONIC LYMPHO-
CYTIC LEUKEMIA
Wu, C.J.1,3, Hainz, U.3, Stevenson, K.E.2, Goldstein, N.P.1,
Brusic, A.M.3, Choi, J.J.3, Pasek, M.1, Brown, J.R.1,
Canning, C.M.1,3, Armand, P.J.1, Koreth, J.1, Cutler, C.1,
Soiffer, R.J.1, Sasada, T.3, Ritz, J.1,3, Dranoff, G.1,3, Alyea, E.P.1 1Da-
na-Farber Cancer Institute, Boston, MA; 2Dana-Farber Cancer Institute,
Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA
We recently demonstrated that early post-transplant vaccination
of patients with myeloid leukemia with irradiated autologous tu-
mor cells, virally transduced to express the potent cytokine adju-
vant GM-CSF, is a promising approach to enhance anti-
leukemia immunity with minimal toxicity (Ho et al, PNAS
2009). Chronic lymphocytic leukemia (CLL) is an ideal disease
to extend this treatment approach since it is incurable by conven-
tional chemotherapy, is sensitive to graft-versus-leukemia effects,
and has readily harvestable leukemia cells. However, viral trans-
duction of lymphoid cells is inefficient, and GM-CSF-based cellu-
lar vaccines have thus far been unavailable for CLL. To address
this limitation, we manufactured K562 cells engineered to secrete
high and consistent levels of GM-CSF (10 micrograms GM-
CSF/106 cells/24 hours), and initiated a phase I study to test the
effects of a post-transplant vaccine consisting of 1 x 107 irradiated
autologous CLL cells together with an equal number of irradiated
bystander GM-K562 cells. CD19 + CD5 +CLL cells were har-
vested from patient peripheral blood or marrow and banked prior
to salvage chemotherapy. To date, we have enrolled 13 patients
with CLL, who had experienced a median of 4 prior therapies
(range 2-8). Median CLL marrow involvement at transplant was
10% (range \5-50%). Patients were conditioned with a fludara-
bine/busulfex-based reduced-intensity regimen prior to infusion
of peripheral blood stem cells from a matched related (4) or unre-
lated (9) donor, and received tacrolimus as GvHD prophylaxis
throughout the vaccination period. Starting on day 30-45, vaccines
were administered as a cycle of 6 vaccines (s.c./i.d., every week x 3,
then every 2 weeks x 3). Ten of 13 patients received at least one
vaccine, and 7 of 10 received 3 or more vaccines. Three of 13 de-
veloped graft-versus-host disease (GvHD) prior to day 45, preclud-
ing vaccination. Four of the 10 vaccinated subjects developed grade
II GvHD. None experienced unexpected toxicities to vaccines. At
a median follow-up of 1 year (range 0.5-2 years), 9 of 10 vaccinated
subjects remain free of disease, and 1 patient remains in partial re-
mission. Our studies reveal that reduced intensity transplant fol-
lowed by early CLL/GM-K562 vaccination is well-tolerated and
does not increase the expected rate of GvHD. Early clinical results
are promising and ongoing studies are assessing the effects of the
vaccination on the induction of immunity against recipient CLL
cells.AUTOIMMUNE DISEASE
27
DENIALS OF TREATMENT COVERAGE BY HEALTH INSURANCE CARRIERS
RESTRICT PATIENT RECRUITMENT ON A RANDOMIZED CLINICAL TRIAL:
EXPERIENCE OF 95 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) EN-
ROLLED IN THE SCOT (SCLERODERMA: CYCLOPHOSPHAMIDE OR
TRANSPLANTATION) TRIAL
Sullivan, K.M.1, Seibold, J.R.2,Mineishi, S.2,Mayes,M.D.3, Hosing, C.4,
Nash, R.A.5, Wener, M.6, Csuka, M.E.7, Bredeson, C.7, Simms, R.8,
Ballen, K.9, Forman, S.10, St Clair, W.E.1, Furst, D.E.11 1Duke Univer-
sity Medical Center, Durham, NC; 2University of Michigan, Ann Arbor,
MI; 3University of Texas-Houston, Houston, TX; 4M.D. Anderson Can-
cer Center, Houston, TX; 5Fred Hutchinson Cancer Research Center, Se-
attle, WA; 6University of Washington, Seattle, WA; 7Medical College of
Wisconsin, Milwaukee, WA; 8Boston University, Boston, MA; 9Massa-
chusetts General Hospital, Boston, MA; 10City of Hope National Medical
Center, Duarte, CA; 11University of California, Los Angeles, CA
Background: Although health insurance coverage decisions can re-
strict recruitment on clinical trials, there are surprisingly few pub-
lished data measuring this effect.
Methods: Subjects with poor prognosis SSc were enrolled on the
ongoing SCOT trial comparing cyclophosphamide with autologous
stem cell transplant. Insurance submissions included evaluations
from SCOT rheumatology and BMT physicians, screening data,
protocol and consents approved by local IRBs, NIH and FDA and
supporting publications. Specific entry criteria and treatments are
further detailed at the study website (www.sclerodermatrial.org).
Results: Requests for coverage for 95 SCOT eligible patients (pts)
were submitted from the 7 BMT centers listed above to 49 health in-
surance plans (54 pts to 28 Blue Cross Blue Shield plans; 26 pts to 12
other commercial plans; and 15 pts to 9 governmental plans). At ini-
tial submission, 44 pts were approved and 51 (54%) were denied cov-
erage. Of the 51 subjects denied coverage, 15 did not appeal and
became ineligible for treatment randomization while 36 filed a first
appeal. Of these 36 pts, 23 were again denied while 13 (36%) were
approved on outside review. Of the 23 pts with first appeal denials,
10 did not file another appeal. Of the 13 filing a second appeal, 7
(54%) were approved. In total, 64/95 (67%) pts were approved on
initial or appeal reviews. The majority of denials were determina-
tions that protocol therapies were ‘‘experimental or investigational’’,
despite supplied published evidence that both SSc treatments yield
promising results (NEJM 2006; 354:2655 and Blood 2007;
110:1388). Time from application through appeals varied from 2-7
months, and for several subjects PFTs further declined during review
making them ineligible for randomization. Approval rates (initial ap-
plication + appeals) varied by carrier: 23/26 (88%) for non-Blue
plans; 33/54 (61%) for Blue plans; and 8/15 (53%) for governmental
plans. Remarkably, within the same plan, payment decisions for the
same protocol and the same type of pt were inconsistent or persistent
in denial despite reversals on outside expert review for prior pts.
Conclusions:Health insurer payment decisions can be arbitrary and
inconsistent. This is the first study with evidence that some insurers
delay and restrict patient access and recruitment on an NIH-spon-
sored randomized trial, thereby impeding clinical research and the




AN ALGORITHMIC APPROACH TO EVALUATE THE OPTIMAL USE OF
PLERIXAFOR (MOZOBIL) FOR AUTOLOGOUS HEMATOPOIETIC PE-
RIPHERAL BLOOD STEM CELL (PBSC) COLLECTIONS BASED ON PERIPH-
ERAL CIRCULATING CD34 COUNTS AND DAY ONE COLLECTION YIELD IN
PATIENTSWITHMULTIPLE MYELOMA (MM) AND LYMPHOMA (NHL, HD)
Abhyankar, S.H.1, Aljitawi, O.1, Ganguly, S.1, McGuirk, J.P.1,
DeJarnette, S.D.2,Merkel,D.A.2 1TheUniversity of KansasMedicalCen-
ter, Kansas City, KS; 2The University of Kansas Hospital, Kansas City, KS
Autologous PBSC transplantation is used as treatment for patients
with MM and lymphoma, but 25-35% of these patients fail to mobi-
lize a sufficient number of PBSC in the first mobilization attempt.
Plerixafor with G-CSF is now often used as a salvage mobilizing reg-
imen in patients failing first attempt with G-CSF alone.
